Feb 28, 2023
|
Lumos Pharma Completes Patient Enrollment in Two Phase 2 OraGrowtH Trials Evaluating Oral LUM-201 in Moderate Idiopathic PGHD
|
|
Feb 15, 2023
|
Lumos Pharma to Report Full Year 2022 Financial Results and Host Conference Call on March 1, 2023
|
|
Jan 3, 2023
|
Lumos Pharma to Participate in 12th Annual LifeSci Partners Corporate Access Event January 9-11, 2023
|
|
Dec 12, 2022
|
KOL Review of Lumos Pharma’s Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients
|
|
Nov 29, 2022
|
Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHD
|
|
Nov 22, 2022
|
Lumos Pharma to Participate in the Piper Sandler 34th Annual Healthcare Conference
|
|
Nov 14, 2022
|
Lumos Pharma Reports Third Quarter 2022 Financial Results and Clinical Development Updates
|
|
Nov 14, 2022
|
Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone Deficiency
|
|
Sep 26, 2022
|
Lumos Pharma to Participate in the Cantor Neurology & Psychiatry Conference
|
|
Aug 31, 2022
|
Lumos Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
|
|